학술논문
The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials.
Document Type
Article
Author
Source
Subject
*AMYOTROPHIC lateral sclerosis treatment
*SYSTEMATIC reviews
*EPIDEMIOLOGY
*CLINICAL trials
*GLUTAMIC acid
*PUBLIC health
*
*
*
*
*
Language
ISSN
1748-2968
Abstract
Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials. [ABSTRACT FROM AUTHOR]